Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

Giuseppe Derosa, Pamela MaffioliDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary goal of diabetes care, given its importance in obtaining a sustained reduction in microvasc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maffioli P, Derosa G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/81f3951fab194831b824de5f399d6fbb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81f3951fab194831b824de5f399d6fbb
record_format	dspace
spelling	oai:doaj.org-article:81f3951fab194831b824de5f399d6fbb2021-12-02T07:45:48ZPatient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes1178-7007https://doaj.org/article/81f3951fab194831b824de5f399d6fbb2011-06-01T00:00:00Zhttp://www.dovepress.com/patient-considerations-and-clinical-utility-of-a-fixed-dose-combinatio-a7772https://doaj.org/toc/1178-7007Giuseppe Derosa, Pamela MaffioliDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary goal of diabetes care, given its importance in obtaining a sustained reduction in microvascular, and possibly macrovascular complications.Aim: The aim of this review was to evaluate the clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.Evidence review: The combination of saxagliptin/metformin was well tolerated and produced sustained glycemic control for up to 76 weeks, with greater improvements in glycemic parameters compared with either drug alone. The saxagliptin/metformin combination also proved its non-inferiority compared with either sulfonylurea/metformin or sitagliptin/metformin combinations.Place in therapy: Clinical practice recommends lifestyle interventions together with starting metformin at the time that the type 2 diabetes mellitus is diagnosed. Once metformin fails to maintain glycemic control, the addition of DPP-4 inhibitors should be the logical choice because of their effects on HbA1c compared to the addition of a sulfonylurea or glitazone, and because of their positive effects on beta cell function and their neutral effects on body weight. Furthermore, DPP-4 inhibitors prevent the risk of hypoglycemia posed by sulfonylureas.Keywords: DPP-4 inhibitors, saxagliptin, glycemic control, insulin sensitivity, HOMA indexMaffioli PDerosa GDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2011, Iss default, Pp 263-271 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Maffioli P Derosa G Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
description	Giuseppe Derosa, Pamela MaffioliDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary goal of diabetes care, given its importance in obtaining a sustained reduction in microvascular, and possibly macrovascular complications.Aim: The aim of this review was to evaluate the clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.Evidence review: The combination of saxagliptin/metformin was well tolerated and produced sustained glycemic control for up to 76 weeks, with greater improvements in glycemic parameters compared with either drug alone. The saxagliptin/metformin combination also proved its non-inferiority compared with either sulfonylurea/metformin or sitagliptin/metformin combinations.Place in therapy: Clinical practice recommends lifestyle interventions together with starting metformin at the time that the type 2 diabetes mellitus is diagnosed. Once metformin fails to maintain glycemic control, the addition of DPP-4 inhibitors should be the logical choice because of their effects on HbA1c compared to the addition of a sulfonylurea or glitazone, and because of their positive effects on beta cell function and their neutral effects on body weight. Furthermore, DPP-4 inhibitors prevent the risk of hypoglycemia posed by sulfonylureas.Keywords: DPP-4 inhibitors, saxagliptin, glycemic control, insulin sensitivity, HOMA index
format	article
author	Maffioli P Derosa G
author_facet	Maffioli P Derosa G
author_sort	Maffioli P
title	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
title_short	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
title_full	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
title_fullStr	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
title_full_unstemmed	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
title_sort	patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/81f3951fab194831b824de5f399d6fbb
work_keys_str_mv	AT maffiolip patientconsiderationsandclinicalutilityofafixeddosecombinationofsaxagliptinmetformininthetreatmentoftype2diabetes AT derosag patientconsiderationsandclinicalutilityofafixeddosecombinationofsaxagliptinmetformininthetreatmentoftype2diabetes
_version_	1718399232241565696

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

Ejemplares similares